Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionBaillie Gifford & Co
Latest Disclosed Ownership6,032,656 shares
Ownership 4.77%
Baillie Gifford & Co ownership in DUL / Alnylam Pharmaceuticals, Inc.

2024-07-05 - Baillie Gifford & Co has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,032,656 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL). This represents 4.77 percent ownership of the company. In their previous filing dated 2024-01-29 , Baillie Gifford & Co had reported owning 6,967,097 shares, indicating a decrease of -13.41 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-07-05 2024-07-05 13G/A 6,967,097 6,032,656 -13.41 4.77 -14.05
2024-01-29 2024-01-29 13G/A 9,407,871 6,967,097 -25.94 5.55 -27.45
2023-01-19 2023-01-19 13G/A 10,616,751 9,407,871 -11.39 7.65 -13.85
2022-01-18 2022-01-18 13G/A 9,132,422 10,616,751 16.25 8.88 12.98
2021-02-01 2021-02-01 13G/A 8,186,723 9,132,422 11.55 7.86 7.08
2020-02-03 2020-02-03 13G 8,186,723 7.34

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 2,493,866 -107,113 -4.12 825,145 -20.22 0.8429
2026-01-23 2025-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 2,600,979 -188,377 -6.75 1,034,279 -18.69 0.8595
2025-10-31 2025-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 2,789,356 -242,535 -8.00 1,271,946 28.65 0.9422
2025-08-06 2025-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 3,031,891 -625,716 -17.11 988,669 0.11 0.7384
2025-05-07 2025-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 3,657,607 -382,652 -9.47 987,627 3.88 0.8619
2025-01-31 2024-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 4,040,259 -846,741 -17.33 950,713 -29.27 0.7305
2024-11-05 2024-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 4,887,000 -1,145,656 -18.99 1,344,072 -8.31 1.0058
2024-07-25 2024-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 6,032,656 -590,921 -8.92 1,465,935 48.09 1.1420
2024-05-01 2024-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 6,623,577 -343,520 -4.93 989,894 -25.77 0.7700
2024-01-26 2023-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 6,967,097 -1,196,042 -14.65 1,333,572 -7.76 1.0568
2023-11-13 2023-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 8,163,139 -229,077 -2.73 1,445,692 -9.31 1.3190
2023-07-28 2023-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 8,392,216 -246,925 -2.86 1,594,018 -7.89 1.3550
2023-05-03 2023-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 8,639,141 -768,730 -8.17 1,730,593 -22.60 1.5615
2023-03-10 2022-12-31 13F/A-1 Alnylam Pharmaceuticals COM 02043Q107 9,407,871 -106,887 -1.12 2,235,781 17.40 2.3299
2023-01-24 2022-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 9,407,871 -106,887 2,236 2.3299
2022-10-27 2022-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 9,514,758 -453,676 -4.55 1,904,474 30.99 1.9636
2022-08-08 2022-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 9,968,434 -171,295 -1.69 1,453,896 -12.19 1.4911
2022-05-05 2022-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 10,139,729 -477,022 -4.49 1,655,716 -8.04 1.1607
2022-01-20 2021-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 10,616,751 200,967 1.93 1,800,388 -8.45 0.9879
2021-10-19 2021-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 10,415,784 190,925 1.87 1,966,605 13.46 1.0289
2021-08-02 2021-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 10,224,859 149,896 1.49 1,733,319 21.85 0.8447
2021-05-06 2021-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 10,074,963 942,541 10.32 1,422,484 19.84 0.7958
2021-02-10 2020-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 9,132,422 240,934 2.71 1,186,941 -8.32 0.6613
2020-11-12 2020-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 8,891,488 242,810 2.81 1,294,600 1.07 0.8915
2020-08-12 2020-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 8,648,678 236,909 2.82 1,280,956 39.90 0.9761
2020-05-08 2020-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 8,411,769 225,046 2.75 915,621 -2.89 0.9920
2020-02-10 2019-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 8,186,723 -49,251 -0.60 942,865 42.35 0.9111
2019-11-07 2019-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 8,235,974 2,022,504 32.55 662,336 46.91 0.7533
2019-08-08 2019-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 6,213,470 528,966 9.31 450,850 -15.13 0.4783
2019-05-01 2019-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 5,684,504 937,654 19.75 531,217 53.49 0.5811
2019-02-14 2018-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 4,746,850 284,024 6.36 346,093 -11.39 0.4496
2018-11-13 2018-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 4,462,826 230,945 5.46 390,587 -6.29 0.4218
2018-07-17 2018-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 4,231,881 397,668 10.37 416,798 -8.73 0.4498
2018-05-10 2018-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 3,834,213 223,199 6.18 456,656 -0.46 0.5356
2018-02-13 2017-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 3,611,014 205,622 6.04 458,779 14.67 0.5704
2017-10-20 2017-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 3,405,392 -25,924 -0.76 400,099 46.19 0.5065
2017-08-10 2017-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 3,431,316 96,805 2.90 273,681 60.15 0.3682
2017-05-12 2017-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 3,334,511 16,489 0.50 170,894 37.57 0.2487
2017-02-14 2016-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 3,318,022 -50,303 -1.49 124,227 -45.59 0.2044
2016-11-09 2016-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 3,368,325 -21,927 -0.65 228,305 21.36 0.3572
2016-08-09 2016-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 3,390,252 10,317 0.31 188,125 -11.33 0.3356
2016-05-05 2016-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 3,379,935 652,201 23.91 212,159 -17.38 0.3734
2016-02-08 2015-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 2,727,734 2,018,484 284.59 256,790 350.55 0.4465
2015-11-05 2015-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 709,250 -82,500 -10.42 56,995 -39.95 0.1116
2015-07-28 2015-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 791,750 -231,680 -22.64 94,907 -11.19 0.1706
2015-05-14 2015-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 1,023,430 -70,000 -6.40 106,866 0.76 0.2022
2015-02-12 2014-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 1,093,430 -97,500 -8.19 106,062 14.03 0.2126
2014-11-07 2014-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 1,190,930 0 0.00 93,011 23.63 0.2039
2014-08-01 2014-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 1,190,930 118,130 11.01 75,231 4.45 0.1625
2014-05-01 2014-03-31 13F Alnylam Pharmaceuticals COM 02043Q107 1,072,800 179,700 20.12 72,027 25.37 0.1696
2014-02-07 2013-12-31 13F Alnylam Pharmaceuticals COM 02043Q107 893,100 140,100 18.61 57,453 19.20 0.1357
2013-11-08 2013-09-30 13F Alnylam Pharmaceuticals COM 02043Q107 753,000 -147,900 -16.42 48,200 72.52 0.1219
2013-08-07 2013-06-30 13F Alnylam Pharmaceuticals COM 02043Q107 900,900 900,900 27,938 0.0848
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.